Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

WBRT and systemic treatments (chemotherapy and/or EGFR TKIs) are the treatment options for polymetastatic involvement of the brain. Treatment approaches are not influenced by the timing of onset ...

However, in the last decade treatment has moved away from some of these modalities, particularly whole-brain radiotherapy, thanks to the efficacy of EGFR tyrosine kinase inhibitors (TKIs).

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are ...

It also is important to emphasize that amivantamab is a bispecific monoclonal antibody that targets EGFR and MET, and lazertinib is a third-generation TKI that targets EGFR. This dual inhibition ...

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, ...